Paper Details

  1. Home
  2. Paper Details

Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.

Author: AntinoriS, BindaF, CalviE, GalliM, GervasoniC, LaiA, MicheliV, MilazzoL, RidolfoA L, RonziP, SollimaS

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

All-oral direct-acting antiviral (DAA) regimens for chronic hepatitis C virus (HCV) infection resulted in high SVR12 rates in both HCV monoinfection and HCV/HIV coinfection. SVR12 rates were 96% in HCV monoinfection and 91% in HCV/HIV coinfection. No predictors of SVR12 were identified.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Clinical trials of all-oral direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection reported high response rates in HCV/HIV coinfection, similar to those obtained in HCV monoinfection. We evaluated the safety and efficacy of these regimens in a clinical practice set...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/hiv.12429

データ提供：米国国立医学図書館（NLM）

Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy

This research examines the safety and efficacy of all-oral direct-acting antivirals (DAAs) in a real-life clinical setting for both HCV-monoinfected and HCV/HIV-coinfected patients. The study analyzes data from a prospective observational study, evaluating sustained virological response (SVR) rates and adverse events (AEs) associated with various DAA regimens.

DAAs Demonstrate High SVR Rates in Real-World Setting

The study's findings demonstrate that all-oral DAA combinations achieve high SVR rates in both HCV-monoinfected and HCV/HIV-coinfected patients under real-world conditions. The SVR12 rates were comparable between the two groups, suggesting that DAAs are effective in treating HCV infection, regardless of coinfection with HIV. Additionally, the study found that historical factors associated with sustained virological response to pegylated interferon and ribavirin (pegIFN/RBV) were not predictive of response to DAAs.

Promising Treatment Options for HCV Infection

This research underscores the significant advances in HCV treatment with the advent of all-oral DAAs. These findings provide compelling evidence for the effectiveness and safety of these regimens, offering promising treatment options for patients with HCV infection, including those coinfected with HIV. Just as a desert oasis provides a vital source of water, DAAs offer a beacon of hope for individuals struggling with HCV infection, offering a chance for sustained viral suppression and improved health outcomes.

Dr.Camel's Conclusion

This real-world study provides valuable insights into the safety and efficacy of all-oral DAAs for HCV infection in both monoinfected and coinfected patients. The study's findings demonstrate the high SVR rates achievable with these regimens, highlighting the potential for significantly improving treatment outcomes for patients with HCV infection. As we continue to explore the vast and complex desert of viral infections, research like this provides a crucial roadmap for developing new and effective therapies that can improve the lives of millions worldwide.

Date :
  1. Date Completed 2017-08-02
  2. Date Revised 2018-03-03
Further Info :

Pubmed ID

27477612

DOI: Digital Object Identifier

10.1111/hiv.12429

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.